Robert Sherrill is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he advises public and private companies on the tax aspects related to domestic and cross-border transactions. He handles a broad range of tax issues, including mergers and acquisitions, joint ventures, restructurings, equity offerings, investment funds, and debt financings.
Experience
Robert Sherrill is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he advises public and private companies on the tax aspects related to domestic and cross-border transactions. He handles a broad range of tax issues, including mergers and acquisitions, joint ventures, restructurings, equity offerings, investment funds, and debt financings.
Education
- J.D., University of Southern California, Gould School of Law, 2024
- B.A., University of North Carolina at Chapel Hill, 2015
Admissions
- State Bar of California
Credentials
Education
- J.D., University of Southern California, Gould School of Law, 2024
- B.A., University of North Carolina at Chapel Hill, 2015
Admissions
- State Bar of California
Select Publications
- Co-author with M. Sutanto Shen, “Eligibility of Life Sciences Companies for Qualified Small Business Stock,” The Life Sciences Report, Wilson Sonsini, January 2025
Insights
Select Publications
- Co-author with M. Sutanto Shen, “Eligibility of Life Sciences Companies for Qualified Small Business Stock,” The Life Sciences Report, Wilson Sonsini, January 2025
Recent Insights
Client Highlights
Firm Advises Forte Biosciences on $2.2 Billion Acquisition by argenx
On July 27, 2026, argenx, a global immunology innovation company, and Forte Biosciences, a clinical-stage biopharmaceutical company, announced that they have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77.00 per share in cash, representing a total equity value of approximately $2.2 billion. FB102, Forte Biosciences’ lead program, expands argenx’s portfolio of differentiated immunology medicines, adding a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Beam Benefits on Acquisition by Principal Financial Group
On July 7, 2026, Principal Financial Group announced an agreement to acquire Beam Benefits, an employee benefits company serving more than 25,000 small businesses. Principal currently serves 180,000 employers, providing comprehensive retirement, benefits, and business owner solutions. The acquisition is expected to close in the latter half of 2026, subject to the completion of customary closing conditions and regulatory approvals. Wilson Sonsini Goodrich & Rosati advised Beam Benefits on the transaction.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.